Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q3 2015 (← Previous) (Next →)

Filing Date: Oct 28, 2015

Total Value: $174.4B (100.0% shares, 0.0% debt)

Holdings (7)

GKOS Glaukos Corporation 43.6%

Value $76.01B Shares 3,142,217 Est. Cost $30.09 Unrealized 0.0%

— Clovis Oncology, Inc. 21.5%

Value $37.47B Shares 407,416 Est. Cost $56000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 17.9%

Value $31.15B Shares 2,215,384 Est. Cost $20.09 Unrealized 0.0%

— Five Prime Therapeutics, Inc. 9.6%

Value $16.81B Shares 1,092,152 Est. Cost $27000.00 Unrealized —

— Achaogen, Inc. 4.2%

Value $7.379B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Biotie Therapies Corp. 2.0%

Value $3.517B Shares 268,672 Est. Cost $19970.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.2%

Value $2.034B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GKOS	Glaukos Corporation	3,142,217	$76.01B	43.6%	$30.09	0.0%	Common Stock	377322102
—	Clovis Oncology, Inc.	407,416	$37.47B	21.5%	$56000.00	—	Common Stock	189464100
OCUL	Ocular Therapeutix, Inc.	2,215,384	$31.15B	17.9%	$20.09	0.0%	Common Stock	67576A100
—	Five Prime Therapeutics, Inc.	1,092,152	$16.81B	9.6%	$27000.00	—	Common Stock	33830X104
—	Achaogen, Inc.	1,281,152	$7.379B	4.2%	$13050.00	—	Common Stock	004449104
—	Biotie Therapies Corp.	268,672	$3.517B	2.0%	$19970.00	—	ADS	09074D103
—	CymaBay Therapeutics, Inc.	1,048,601	$2.034B	1.2%	$9830.00	—	Common Stock	23257D103